Crohn's Disease: Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn’s Disease

Category Primary study
Registry of TrialsClinical Trials Information System
Year 2025
This article has no abstract
Epistemonikos ID: 622eb6e2789c7e89209cf652d5a0db5245bd5c55
First added on: Jan 17, 2026